Immunotherapy Program at Northside
Northside Hospital’s Immunotherapy Program is a nationally recognized treatment center.
Northside Hospital’s Immunotherapy and CAR T-cell Program FACTS:
Within five to ten business days of the initial referral, the relapsed or refractory non-Hodgins’s lymphoma patient, acute lymphocytic leukemia, or multiple myeloma patient will be evaluated by the Northside Hospital’s immunotherapy and CAR T-cell physicians.
Dedicated cellular therapy clinical coordinators will organize and coordinate care from new patient consultation through treatment follow-up.
With onsite apheresis capabilities at Atlanta Blood Services, our team is able to schedule T-cell apheresis within days of a new patient's consultation.
Dedicated financial team that is able to expeditiously obtain financial approval for all immunotherapy treatments, including CAR T-cell.
Continuous communication with referring hematologists and oncologists to ensure bridging therapy is initiated if necessary.
Please visit immunotherapy clinical trials for a listing of leukemia, multiple myeloma, diffuse large B-cell lymphoma, and other various disease-specific immunotherapy trials.
Available Commercial CAR T-cell Products:
B-CELL MALIGNANCIES
BREYANZI®
Relapsed/Refractory (R/R) Large B-Cell Lymphoma, including:
· Diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from indolent lymphoma
· High-grade B-cell lymphoma
· Primary mediastinal large B-cell lymphoma
· Follicular lymphoma grade 3B
» Adult patients (18+ years)
» Refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line
chemoimmunotherapy-OR-
» Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age-OR-
» After two (2) or more lines of systemic therapy
TECARTUS®
Relapsed/Refractory (R/R) Mantle Cell Lymphoma
Adult patients (18+ years)
After first line therapy
YESCARTA®
Relapsed/Refractory Large B-cell lymphoma
» Adult patients (18+ years)
» Refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line
chemoimmunotherapy
Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma including:
· Diffuse large B-cell lymphoma not otherwise specified
· DLBCL arising from follicular lymphoma
· High-grade B-cell lymphoma
· Primary mediastinal large B-cell lymphoma
» Adult patients (18+ years)
» After two (2) or more lines of systemic therapy
KYMRIAH®
Relapsed/Refractory (R/R) Large B-Cell Lymphoma, including:
· Diffuse large B-cell lymphoma not otherwise specified
· DLBCL arising from follicular lymphoma
· High-grade B-cell lymphoma
· Follicular lymphoma
» Adult patients (18+ years)
» After two (2) or more lines of systemic therapy
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
TECARTUS®
Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
» Adult Patients (18+ Years)
KYMRIAH®
B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
» Patients ≤ 25 years
» ALL is refractory or in a second or later relapse
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL):
TECARTUS®
Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Adult Patients (18+ Years)
KYMRIAH®
B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Patients ≤ 25 years
ALL is refractory or in a second or later relapse.
MULTIPLE MYELOMA
ABECMA®
Relapsed/Refractory (R/R) Multiple Myeloma*
After four (4) or more prior lines of therapy, including:
» an immunomodulatory agent
» a proteasome inhibitor
» an anti-CD-38 monoclonal antibody
CARVYKTI[KM1] ®
After four (4) or more prior lines of therapy, including:
» an immunomodulatory agent
» a proteasome inhibitor
» an anti-CD-38 monoclonal antibody